PROVISION OF TUMOUR PROFILING TEST
NHS South West - Acutes · Awarded
- Buyer
- NHS South West - Acutes
- Status
- Awarded
- Country
- United Kingdom
- Region
- England
- Sector
- Manufacturing
- Reference
- FaT-ocds-h6vhtk-0330a5
- Published
- 2022-04-26
- Deadline
- 2026-05-07
Tender summary
Nice guidelines recommend Endopredict, Oncotype DX or Prosigna Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Of these 3 tests it has been confirmed that Oncotype DX is the only one available under the framework, Contract Ref. Pathology and Point of Care Testing, Associated Equipment, Instruments, Consumables and Accessories and Managed Services (2019/S 212-519575). A direct award has been made to Exact Sciences for Oncotype DX for the following reason: Specialist expertise is required and only available from one source.
This is a public summary of a procurement notice. Dates and status reflect the notice held by BidScout; check the full notice before bidding.
Full tender details have a three-minute guest preview for open opportunities. AI insights require registration.
Register for full access